<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29673" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sulfonylureas</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Costello</surname>
            <given-names>Ryan A.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nicolas</surname>
            <given-names>Samar</given-names>
          </name>
          <aff>MCPHS University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shivkumar</surname>
            <given-names>Abhijit</given-names>
          </name>
          <aff>St. Bernards Hospital, Jonesboro-AR</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ryan Costello declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Samar Nicolas declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abhijit Shivkumar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29673.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Sulfonylureas represent a class of medications utilized in the treatment of type 2 diabetes mellitus. This activity outlines the indications, mechanism of action, administration, adverse effects, contraindications, monitoring, and toxicity of sulfonylureas. The importance of utilizing a multi-disciplinary approach to managing patients taking sulfonylureas will also be highlighted.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mechanism of action of sulfonylureas.</p></list-item><list-item><p>Explain the potential adverse effects of sulfonylureas.</p></list-item><list-item><p>Review sulfonylurea overdoses and the treatment options available.</p></list-item><list-item><p>Summarize the importance of utilizing an interprofessional team approach to caring for diabetic patients taking sulfonylureas.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29673&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29673">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29673.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Sulfonylureas are the oldest class of oral antidiabetic medication dating back to the 1950s.<xref ref-type="bibr" rid="article-29673.r1">[1]</xref> All sulfonylureas contain a phenyl-sulfonyl-urea structure, which exerts the hypoglycemic effect.<xref ref-type="bibr" rid="article-29673.r2">[2]</xref> Patients with type 2 diabetes mellitus use sulfonylureas as monotherapy or in combination with other oral or injectable medications.<xref ref-type="bibr" rid="article-29673.r3">[3]</xref><xref ref-type="bibr" rid="article-29673.r4">[4]</xref><xref ref-type="bibr" rid="article-29673.r5">[5]</xref>&#x000a0;Sulfonylureas are divided into first-generation and second-generation. The first-generation sulfonylureas include chlorpropamide and tolbutamide.<xref ref-type="bibr" rid="article-29673.r6">[6]</xref> Chlorpropamide is no&#x000a0;longer available in the United States. The second-generation sulfonylureas include glyburide (also known as glibenclamide), glipizide, glimepiride, and gliclazide. Gliclazide is not available in the United States.<xref ref-type="bibr" rid="article-29673.r7">[7]</xref> Glimepiride came to market in 1995, and it is the newest sulfonylurea.<xref ref-type="bibr" rid="article-29673.r8">[8]</xref> Some references list glimepiride as a third-generation sulfonylurea because its chemical structure has a larger substitution moiety than the other second-generation sulfonylureas.<xref ref-type="bibr" rid="article-29673.r9">[9]</xref></p>
        <p>Sulfonylureas are comparable in efficacy and decrease the glycated hemoglobin A1C (HbA1c) by 1% to 1.25%.<xref ref-type="bibr" rid="article-29673.r10">[10]</xref><xref ref-type="bibr" rid="article-29673.r11">[11]</xref><xref ref-type="bibr" rid="article-29673.r12">[12]</xref><xref ref-type="bibr" rid="article-29673.r13">[13]</xref>&#x000a0;Second-generation sulfonylureas are among the most used anti-diabetic medications because they are inexpensive.<xref ref-type="bibr" rid="article-29673.r4">[4]</xref> Providers rarely prescribe first-generation sulfonylureas nowadays.<xref ref-type="bibr" rid="article-29673.r14">[14]</xref> Sulfonylureas are not preferred for elderly patients and those with renal or hepatic impairment.<xref ref-type="bibr" rid="article-29673.r4">[4]</xref> Patients with type 2 diabetes can take sulfonylureas in combination with any other oral antidiabetic medication except the meglitinides (nateglinide and repaglinide).<xref ref-type="bibr" rid="article-29673.r5">[5]</xref></p>
        <p>Similar to sulfonylureas, meglitinides stimulate the pancreatic beta cells to secrete insulin.<xref ref-type="bibr" rid="article-29673.r15">[15]</xref> Clinicians often prescribe sulfonylurea as an add-on to metformin.<xref ref-type="bibr" rid="article-29673.r16">[16]</xref> This combination targets different mechanisms of action and improves glucose control; sulfonylureas stimulate insulin secretion while metformin increases insulin sensitivity. An advantage to this combination is the potential for a neutral effect on the patient&#x02019;s body weight since sulfonylureas cause weight gain while metformin causes weight loss.<xref ref-type="bibr" rid="article-29673.r16">[16]</xref> A Canadian study showed the combination of acarbose and sulfonylurea to have beneficial effects on HbA1c levels. The combination of sulfonylureas with thiazolidinediones improves glycemic control.&#x000a0;</p>
      </sec>
      <sec id="article-29673.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Sulfonylureas bind to and inhibit the ATP-sensitive potassium channels (K) on the pancreatic beta cells. As a result, potassium efflux decreases, and the beta-cell membrane depolarizes. Membrane depolarization causes calcium channels to open, leading to calcium influx and increased intracellular calcium, which stimulates insulin secretion from the pancreatic beta cells.<xref ref-type="bibr" rid="article-29673.r17">[17]</xref><xref ref-type="bibr" rid="article-29673.r2">[2]</xref> Sulfonylureas cause insulin release regardless of blood glucose levels.<xref ref-type="bibr" rid="article-29673.r18">[18]</xref> K is made of two proteins, Kir6.2 that forms the pore of the K channels, and a sulfonylurea receptor (SUR).<xref ref-type="bibr" rid="article-29673.r19">[19]</xref> SUR1 and SUR2 are subtypes of SUR.<xref ref-type="bibr" rid="article-29673.r20">[20]</xref></p>
        <p>The SUR1 is mostly present in the brain and on the beta cells in the pancreas. SUR2 is present in the cardiac muscle (as isoform SUR2A) and the smooth muscle (as isoform SUR2B). Sulfonylureas differ in their affinity to the SUR subtype receptors and their efficacy in closing the K channels. Unlike the other sulfonylureas, glimepiride has a lower affinity to the cardiac muscles and is not associated with cardiovascular safety concerns.<xref ref-type="bibr" rid="article-29673.r18">[18]</xref> Sulfonylureas also lower the serum glucose levels by decreasing insulin metabolism in the liver, decreasing glucagon secretion, and increasing sensitivity to insulin in peripheral tissues.<xref ref-type="bibr" rid="article-29673.r21">[21]</xref></p>
      </sec>
      <sec id="article-29673.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Start sulfonylureas at a low dose and titrate up based on glycemic control.<xref ref-type="bibr" rid="article-29673.r4">[4]</xref> The Kidney Disease Improving Global Outcomes (KDIGO) 2020 guideline lists sulfonylureas in the least suitable category of antidiabetic medications for patients with eGFR &#x0003c; 15 mL/min/1.73 m^2.<xref ref-type="bibr" rid="article-29673.r22">[22]</xref></p>
        <p>Chlorpropamide is a long-acting sulfonylurea available as 100 mg and 250 mg oral tablets outside the United States.<xref ref-type="bibr" rid="article-29673.r5">[5]</xref><xref ref-type="bibr" rid="article-29673.r6">[6]</xref> Start at 100 mg to 250 mg daily and increase the dose slowly every 5 to 7 days. The maximum daily dose for chlorpropamide is 750 mg.</p>
        <p>Tolbutamide is a short-acting sulfonylurea available as a 500 mg oral tablet.<xref ref-type="bibr" rid="article-29673.r5">[5]</xref><xref ref-type="bibr" rid="article-29673.r6">[6]</xref> Start at 1000 mg to 2000 mg once daily or in two divided doses. The maximum daily dose for tolbutamide is 3000 mg.&#x000a0;</p>
        <p>Glyburide is a long-acting sulfonylurea available as an immediate-release (IR) oral tablet.<xref ref-type="bibr" rid="article-29673.r5">[5]</xref><xref ref-type="bibr" rid="article-29673.r3">[3]</xref> Glyburide's starting dose is 2.5 mg to 5 mg daily with a maximum dose of 20 mg per day.<xref ref-type="bibr" rid="article-29673.r3">[3]</xref> Food does not delay glyburide absorption. Therefore, administer the scheduled dose of glyburide with a meal.<xref ref-type="bibr" rid="article-29673.r23">[23]</xref> Reduce glyburide dose in patients with an estimated glomerular filtration rate (eGFR) 60&#x000a0;to 90 mL/min/1.73 mand avoid it in patients with eGFR &#x0003c; 60 mL/min/1.73 m^2.<xref ref-type="bibr" rid="article-29673.r24">[24]</xref></p>
        <p>Glipizide is available in an IR and an extended-release (ER) oral tablet.<xref ref-type="bibr" rid="article-29673.r3">[3]</xref> Glipizide IR has an intermediate duration of action, and glipizide ER has a long duration of action.<xref ref-type="bibr" rid="article-29673.r5">[5]</xref> The starting dose is 5 mg per day for both formulations. The maximum daily dose of glipizide IR is 40 mg per day, while the maximum dose for glipizide ER is 20 mg per day.<xref ref-type="bibr" rid="article-29673.r3">[3]</xref> Food delays the absorption of glipizide IR by 30 minutes, which leads to a delay in onset of action and less control of blood glucose. Therefore, administer the scheduled dose of glipizide IR 30 minutes before a meal; this allows enough time for insulin release and glucose control in response to food ingestion.<xref ref-type="bibr" rid="article-29673.r25">[25]</xref> Administer glipizide ER with a meal. The American Diabetes Association (ADA) guideline recommends starting glipizide at a conservative dose in patients with chronic kidney disease (CKD) to avoid hypoglycemia.<xref ref-type="bibr" rid="article-29673.r26">[26]</xref></p>
        <p>Glimepiride is available as an IR oral tablet. Start glimepiride at 1 to 2 mg per day and a maximum daily dose of 8 mg.<xref ref-type="bibr" rid="article-29673.r3">[3]</xref> Administer glimepiride with or up to 30 minutes after a meal.<xref ref-type="bibr" rid="article-29673.r9">[9]</xref> In patients with CKD, initiate glimepiride conservatively to avoid hypoglycemia and avoid its use in patients with eGFR &#x0003c; 15&#x000a0;mL/min/1.73 m^2.<xref ref-type="bibr" rid="article-29673.r26">[26]</xref><xref ref-type="bibr" rid="article-29673.r27">[27]</xref></p>
        <p>Gliclazide is available as an IR oral tablet and a modified release (MR) oral tablet. Administer immediate release gliclazide two times daily, 30 minutes before a meal.<xref ref-type="bibr" rid="article-29673.r28">[28]</xref> Gliclazide IR is available as an 80 mg tablet, and&#x000a0;the maximum daily dose is 320 mg.<xref ref-type="bibr" rid="article-29673.r29">[29]</xref> Gliclazide MR is available in 30 mg and 60 mg tablets.<xref ref-type="bibr" rid="article-29673.r30">[30]</xref> Administer gliclazide MR once daily with a meal with a maximum dose of 120 mg per day.<xref ref-type="bibr" rid="article-29673.r30">[30]</xref><xref ref-type="bibr" rid="article-29673.r31">[31]</xref></p>
        <p>If a patient is fasting, reduce or hold the sulfonylurea dose and ensure self-monitoring of glucose levels.<xref ref-type="bibr" rid="article-29673.r32">[32]</xref></p>
      </sec>
      <sec id="article-29673.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Sulfonylureas stimulate insulin secretion regardless of the serum glucose levels.<xref ref-type="bibr" rid="article-29673.r33">[33]</xref> Therefore,&#x000a0;hypoglycemia is the most common side effect and a major concern associated with sulfonylureas.<xref ref-type="bibr" rid="article-29673.r2">[2]</xref> Hypoglycemia occurs when blood glucose levels drop below 70 mg/dL.<xref ref-type="bibr" rid="article-29673.r34">[34]</xref> Patients may experience sweating, shakiness, irritability, confusion, tachycardia, and a feeling of hunger. Hypoglycemia may be severe, especially after a missed meal, exercise, or taking sulfonylureas at a high dose.<xref ref-type="bibr" rid="article-29673.r35">[35]</xref><xref ref-type="bibr" rid="article-29673.r36">[36]</xref><xref ref-type="bibr" rid="article-29673.r4">[4]</xref><xref ref-type="bibr" rid="article-29673.r37">[37]</xref>&#x000a0;Glipizide, glimepiride, and gliclazide are associated with a lower incidence of hypoglycemia compared to glyburide.<xref ref-type="bibr" rid="article-29673.r4">[4]</xref><xref ref-type="bibr" rid="article-29673.r38">[38]</xref> Because sulfonylureas bind to plasma proteins with high affinity, the risk of hypoglycemia increases when certain medications displace sulfonylureas from their plasma protein binding sites. Examples include sulfonamides, gemfibrozil, and warfarin.<xref ref-type="bibr" rid="article-29673.r39">[39]</xref></p>
        <p>Weight gain is common with sulfonylureas.<xref ref-type="bibr" rid="article-29673.r40">[40]</xref> The ADA guideline recommends considering the patient&#x02019;s weight when selecting an antidiabetic drug.<xref ref-type="bibr" rid="article-29673.r41">[41]</xref> Avoid prescribing sulfonylureas to obese patients.<xref ref-type="bibr" rid="article-29673.r40">[40]</xref></p>
        <p>Other common side effects include nausea, diarrhea, dizziness, and headache.<xref ref-type="bibr" rid="article-29673.r7">[7]</xref> Chlorpropamide and tolbutamide cause facial flushing with alcohol.<xref ref-type="bibr" rid="article-29673.r42">[42]</xref></p>
        <p>The University Group Diabetes Program (UGDP) trial showed an increased risk of mortality with tolbutamide.<xref ref-type="bibr" rid="article-29673.r43">[43]</xref> As a result, the Food and Drug Administration (FDA) required a boxed warning about the increased risk of cardiovascular events with all sulfonylureas and that manufacturers must prove the cardiovascular safety of all new antidiabetic medications.<xref ref-type="bibr" rid="article-29673.r44">[44]</xref></p>
        <p>Glimepiride is not associated with an increased cardiovascular risk.<xref ref-type="bibr" rid="article-29673.r43">[43]</xref> The Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) showed the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, to have neutral cardiovascular safety effects.<xref ref-type="bibr" rid="article-29673.r45">[45]</xref> The Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients with Type 2 Diabetes (CAROLINA) showed similar cardiovascular outcomes between glimepiride and linagliptin.<xref ref-type="bibr" rid="article-29673.r46">[46]</xref></p>
        <p>The ADA guideline recommends metformin as a first-line agent for all patients with type 2 diabetes unless contraindicated.<xref ref-type="bibr" rid="article-29673.r26">[26]</xref> Studies have shown other antidiabetic drug classes to be as effective as sulfonylureas in lowering HbA1c.&#x000a0;<xref ref-type="bibr" rid="article-29673.r1">[1]</xref> Oral antidiabetic agents, except meglitinides (i.e., nateglinide and repaglinide), pose less risk of hypoglycemia than sulfonylureas.<xref ref-type="bibr" rid="article-29673.r47">[47]</xref> Some of the newer antidiabetic drug classes have shown to have either neutral cardiovascular effects or cardiovascular benefits.<xref ref-type="bibr" rid="article-29673.r44">[44]</xref> Therefore, in the absence of financial restrictions and given the availability of safer alternatives, patients should not receive sulfonylureas as second-line agents.<xref ref-type="bibr" rid="article-29673.r1">[1]</xref> If a sulfonylurea is necessary for an elderly patient, the ADA guideline recommends using glipizide or glimepiride over glyburide since they are shorter acting and associated with less risk of hypoglycemia.<xref ref-type="bibr" rid="article-29673.r48">[48]</xref></p>
      </sec>
      <sec id="article-29673.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The Beers Criteria for potentially inappropriate medication use in older adults includes chlorpropamide and glyburide.<xref ref-type="bibr" rid="article-29673.r49">[49]</xref> Older adults may experience prolonged hypoglycemia with these long-acting agents. Chlorpropamide can also cause the syndrome of inappropriate antidiuretic hormone secretion. The 2012 American Geriatric Society Beers Criteria highly recommends and with strong evidence to avoid chlorpropamide and glyburide in older adults.&#x000a0;</p>
        <p>There is a debate whether hypersensitivity to sulfonamides is a contraindication to prescribing sulfonylureas.<xref ref-type="bibr" rid="article-29673.r50">[50]</xref> A literature review suggested that patients with allergies to sulfonamides may not need to avoid sulfonylureas.<xref ref-type="bibr" rid="article-29673.r51">[51]</xref> However, given the small number of patients reviewed, there is limited data to confirm or refute the need to avoid sulfonylureas in patients with sulfa allergy. The medication package insert provides the FDA-approved product information, including contraindications.<xref ref-type="bibr" rid="article-29673.r52">[52]</xref> Providers should review this information carefully. The court may determine a provider to be negligent if they prescribe a contraindicated medication that causes harm to a patient.<xref ref-type="bibr" rid="article-29673.r52">[52]</xref></p>
        <p>Oral antidiabetic agents, including sulfonylureas, are not FDA-approved for use in pregnancy and lactation.<xref ref-type="bibr" rid="article-29673.r53">[53]</xref> However, according to the National Institute for Health and Clinical Excellence (NICE) guidance, glyburide is safe in pregnancy and lactation.<xref ref-type="bibr" rid="article-29673.r54">[54]</xref> The Endocrine Society supports the NICE guidance in recommending glyburide for gestational diabetes in selected patients.<xref ref-type="bibr" rid="article-29673.r53">[53]</xref></p>
        <p>The ADA guideline recommends avoiding glyburide in patients with CKD.<xref ref-type="bibr" rid="article-29673.r26">[26]</xref></p>
      </sec>
      <sec id="article-29673.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The ADA guideline recommends monitoring HbA1c levels at least quarterly after therapy change or if patients do not meet glycemic goals.<xref ref-type="bibr" rid="article-29673.r55">[55]</xref> Providers can monitor HbA1c levels less frequently but at least twice a year in patients who meet their glycemic goal.&#x000a0;</p>
        <p>For patients with diabetes mellitus type 2 on insulin therapy, the ADA guideline recommends self-monitoring of blood glucose (SMBG) to decrease the risk of hypoglycemia and manage hyperglycemia.<xref ref-type="bibr" rid="article-29673.r56">[56]</xref> However, the benefits of SMBG in achieving the desired glycemic control in patients who are not using insulin are debatable.<xref ref-type="bibr" rid="article-29673.r57">[57]</xref> A meta-analysis showed that SMBG effectively guides therapy and reduces HbA1c levels for patients who are not on insulin therapy. For patients on oral hypoglycemic medications, including sulfonylureas, patient-specific factors determine the need for SMBG and testing frequency.&#x000a0;&#x000a0;</p>
        <p>Monitor patients for hypoglycemia with sulfonylureas.</p>
        <p>Monitor serum creatinine once a year or every 3 to 4 months in selected patients and adjust the sulfonylurea dose accordingly.<xref ref-type="bibr" rid="article-29673.r58">[58]</xref> Risk of hypoglycemia increases in patients with an estimated glomerular filtration rate (eGFR) &#x0003c; 60 mL/min/1.73 m^2.<xref ref-type="bibr" rid="article-29673.r59">[59]</xref></p>
        <p>Instruct patients to perform self-glucose monitoring when they develop symptoms of hypoglycemia.<xref ref-type="bibr" rid="article-29673.r1">[1]</xref> Patients should share this information with their health care provider to guide therapy adjustment.&#x000a0;</p>
      </sec>
      <sec id="article-29673.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Sulfonylureas have a narrow therapeutic index.<xref ref-type="bibr" rid="article-29673.r35">[35]</xref> Hypoglycemia is the most common toxicity associated with intentional or accidental overdose of sulfonylureas and may take up to 12 hours to occur.<xref ref-type="bibr" rid="article-29673.r35">[35]</xref><xref ref-type="bibr" rid="article-29673.r60">[60]</xref> Some symptoms of hypoglycemia are shakiness, irritability, tachycardia, confusion, and hunger. <xref ref-type="bibr" rid="article-29673.r55">[55]</xref> In severe cases, hypoglycemia may lead to loss of consciousness, seizure, coma, or death. In children ages 1 to 4 years old, hypoglycemia occurred with the accidental ingestion of one of the following: chlorpropamide 250 mg, glipizide 5 mg, or glyburide 2.5 mg. <xref ref-type="bibr" rid="article-29673.r61">[61]</xref></p>
        <p>Educate patients that the hypoglycemia alert value is &#x02264; 70 mg/dL (3.9 mmol/L).<xref ref-type="bibr" rid="article-29673.r62">[62]</xref>&#x000a0; The ADA guideline recommends 15 to 20 grams of pure oral glucose as the treatment of choice for hypoglycemia.<xref ref-type="bibr" rid="article-29673.r55">[55]</xref> Pure glucose provides a better response than food containing carbohydrates. Fat content may delay response to the carbohydrate-containing food, and protein may worsen the hypoglycemic episodes by stimulating insulin release without increasing blood glucose levels.<xref ref-type="bibr" rid="article-29673.r63">[63]</xref></p>
        <p>The &#x0201c;Rule of 15&#x0201d; or &#x0201c;15-15&#x0201d; rule applies to treatment with glucose. The patient should receive 15 grams of glucose, recheck blood glucose levels 15 minutes later, and repeat the process as needed until hypoglycemia resolves.<xref ref-type="bibr" rid="article-29673.r64">[64]</xref> Sources of oral glucose include, but are not limited to, glucose tablets, juice, or soft drink.<xref ref-type="bibr" rid="article-29673.r35">[35]</xref> Depending on the duration of action of the sulfonylurea responsible for the overdose, hypoglycemia may reoccur.<xref ref-type="bibr" rid="article-29673.r62">[62]</xref> Educate patients to eat a meal or a snack once their serum glucose is normal or trending up to prevent a recurrent hypoglycemic episode.<xref ref-type="bibr" rid="article-29673.r62">[62]</xref><xref ref-type="bibr" rid="article-29673.r55">[55]</xref></p>
        <p>In hospitalized patients, intravenous (IV) dextrose is the first-line therapy for severe hypoglycemia from sulfonylureas.<xref ref-type="bibr" rid="article-29673.r35">[35]</xref> Patients may require a continuous IV infusion of dextrose to prevent recurrent hypoglycemia, especially with long-acting sulfonylureas.<xref ref-type="bibr" rid="article-29673.r65">[65]</xref> Check blood glucose levels every 15 minutes.<xref ref-type="bibr" rid="article-29673.r66">[66]</xref></p>
        <p>Glucagon stimulates glucose production in the liver and is useful for patients who refuse or cannot take oral glucose.&#x000a0;<xref ref-type="bibr" rid="article-29673.r62">[62]</xref> Glucagon is available in different formulations for various routes of administration.<xref ref-type="bibr" rid="article-29673.r67">[67]</xref> The powder for injection requires reconstitution before intramuscular or subcutaneous administration. Newer formulations of glucagon that patients may favor do not require reconstitution. The FDA approved glucagon nasal powder in July 2019, which is a convenient portable dry spray. In September 2019, the FDA approved a solution for subcutaneous injection available in a prefilled syringe and an autoinjector. Educate&#x000a0;all patients and their caregivers on proper glucagon administration techniques.<xref ref-type="bibr" rid="article-29673.r62">[62]</xref></p>
        <p>Octreotide is a somatostatin analog that results in an effect opposite to that of sulfonylureas. By binding to the somatostatin-2 receptors on the pancreatic beta cells, octreotide inhibits calcium influx, thus blocking insulin secretion.<xref ref-type="bibr" rid="article-29673.r35">[35]</xref> Since IV dextrose corrects hypoglycemia but may trigger insulin secretion and a recurrence of hypoglycemia, administering octreotide blocks the undesired insulin secretion in response to IV dextrose. Evidence supports the use of octreotide for hypoglycemia induced by sulfonylureas when dextrose alone does not normalize the blood glucose.<xref ref-type="bibr" rid="article-29673.r60">[60]</xref> There is a debate&#x000a0;regarding the best time to administer octreotide. Some experts recommend reserving octreotide to patients who experience recurrent hypoglycemia, while others recommend a proactive approach of initiating octreotide after the first hypoglycemic episode.<xref ref-type="bibr" rid="article-29673.r35">[35]</xref></p>
        <p>Monitor all patients for 12 hours after hypoglycemia treatment to recognize and treat recurrent episodes.<xref ref-type="bibr" rid="article-29673.r35">[35]</xref></p>
      </sec>
      <sec id="article-29673.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Diabetes mellitus is a chronic condition that can negatively affect various organ systems.<xref ref-type="bibr" rid="article-29673.r68">[68]</xref> Diabetes is a major public health problem that has been on the rise.<xref ref-type="bibr" rid="article-29673.r69">[69]</xref><xref ref-type="bibr" rid="article-29673.r70">[70]</xref> Patients taking antidiabetic medications, including sulfonylureas, assess their HbA1c at least twice a year if they have been stable within therapeutic goals. Assess HbA1c at least three times a year if diabetes is uncontrolled.<xref ref-type="bibr" rid="article-29673.r55">[55]</xref>&#x000a0;[Level 5]</p>
        <p>Available data supports an interprofessional team approach in diabetes care. An interprofessional healthcare team model for diabetes care may include clinicians (MDs, DOs, NPs, PAs), nurses, diabetes educators, dietitians, and pharmacists. Providers from different professions complement each other to improve patient outcomes and decrease healthcare costs.<xref ref-type="bibr" rid="article-29673.r71">[71]</xref></p>
        <p>A clinician-pharmacist collaborative practice is beneficial to patients with diabetes.<xref ref-type="bibr" rid="article-29673.r72">[72]</xref> This practice promotes better diabetes control with a reduction in HbA1c, reducing low-density lipoprotein (LDL) levels, improved screening for microalbuminuria, and an increased number of annual eye and foot exams. Pharmacists can also play a major role in interviewing patients to obtain an accurate medication history, identifying medication non-adherence, and adjusting medication regimens.<xref ref-type="bibr" rid="article-29673.r73">[73]</xref></p>
        <p>Evidence supports implementing nurse champion models, including nurses, certified diabetes educators, and clinical mentors for diabetes care.<xref ref-type="bibr" rid="article-29673.r71">[71]</xref> A nurse champion model results in a win-win situation for hospitals and patients. Hospitals save money by decreasing readmission rates and medication errors. Patients experience improved quality of life, reduction in HbA1c, decreased hospital readmissions, and greater weight loss. Overall, this collaborative effort leads to a higher standard of care for patients with diabetes.&#x000a0;</p>
        <p>Dietitians serve as an invaluable resource for patients with diabetes. The evidence-based practice guideline by the Academy of Nutrition and Dietetics strongly supports dietitians in providing medical nutrition therapy to improve patient outcomes.<xref ref-type="bibr" rid="article-29673.r74">[74]</xref></p>
        <p>The healthcare team should follow a patient-centered approach and tailor diabetes therapy to the patient&#x02019;s needs.<xref ref-type="bibr" rid="article-29673.r75">[75]</xref> The therapeutic plan should include the management of other risk factors or diabetes complications. The healthcare team should encourage physical activity and a healthy lifestyle, including smoking cessation and weight management, and treat hypertension and dyslipidemia to decrease cardiovascular risk. The healthcare team should identify and address barriers to medication adherence. [Level 2] For example, if the patient is diagnosed with depression, then treating depression effectively may improve medication adherence for chronic conditions like diabetes.<xref ref-type="bibr" rid="article-29673.r76">[76]</xref></p>
        <p>The healthcare team should realize that food insecurity might complicate diabetes. Patients who do not have access to nutritious, healthy food may experience hyperglycemia, and patients who are unable to obtain food may experience hypoglycemia.<xref ref-type="bibr" rid="article-29673.r75">[75]</xref> Whenever possible, the healthcare team should seek resources available in the community to help patients overcome food insecurity. [Level 5]</p>
        <p>As mentioned before, hypoglycemia is a common adverse effect associated with sulfonylureas. Severe hypoglycemia may lead to serious consequences, including seizure, coma, or death. To minimize the risk of hypoglycemic events, the healthcare team should identify patients at risk of hypoglycemia and consider less stringent HbA1c goals.<xref ref-type="bibr" rid="article-29673.r55">[55]</xref>&#x000a0;[Level 3] In addition, reassess the target HbA1c levels over time as the goals might change based on the patient&#x02019;s age and comorbidities. [Level 5] Inquire about episodes of hypoglycemia during each patient encounter. Remind patients and their caregivers to react to a serum glucose level of&#x000a0;less than or equal to&#x000a0;70 mg/dL by consuming glucose. Remind them about the &#x0201c;15-15&#x0201d; rule. [Level 2] During each visit, assess their glucagon injection technique. Ensure that everyone involved in the patient&#x02019;s care knows where glucagon is and remind them to replace the product before the expiration date.<xref ref-type="bibr" rid="article-29673.r55">[55]</xref>&#x000a0;[Level 5]</p>
        <p>While newer and potentially safer alternatives are now available,&#x000a0;sulfonylureas can be a useful adjunct in diabetes management, especially when the cost of therapy is an issue. Successful therapy requires a collaborative interprofessional effort to maximize the therapeutic efficacy of sulfonylureas while minimizing potential adverse events. [Level 5]</p>
      </sec>
      <sec id="article-29673.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29673&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29673">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29673/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29673">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29673.s11">
        <title>References</title>
        <ref id="article-29673.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Genuth</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on!</article-title>
            <source>Diabetes Care</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>170</fpage>
            <page-range>170-5</page-range>
            <pub-id pub-id-type="pmid">25538314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Confederat</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Constantin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lupa&#x0015f;cu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>P&#x000e2;nzariu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>H&#x00103;ncianu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Profire</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.</article-title>
            <source>Rev Med Chir Soc Med Nat Iasi</source>
            <year>2015</year>
            <season>Apr-Jun</season>
            <volume>119</volume>
            <issue>2</issue>
            <fpage>579</fpage>
            <page-range>579-84</page-range>
            <pub-id pub-id-type="pmid">26204670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaughan</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Rueda</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Samson</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Hyman</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Reducing the Burden of Diabetes Treatment: A Review of Low-cost Oral Hypoglycemic Medications.</article-title>
            <source>Curr Diabetes Rev</source>
            <year>2020</year>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>851</fpage>
            <page-range>851-858</page-range>
            <pub-id pub-id-type="pmid">32026779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sola</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schianca</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Maffioli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bigliocca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mella</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Corlian&#x000f2;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fra</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Bartoli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Derosa</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Sulfonylureas and their use in clinical practice.</article-title>
            <source>Arch Med Sci</source>
            <year>2015</year>
            <month>Aug</month>
            <day>12</day>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>840</fpage>
            <page-range>840-8</page-range>
            <pub-id pub-id-type="pmid">26322096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bahendeka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Md</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Orabi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ramaiya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Al Shammari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shaikh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abhayaratna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Mahalingam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Askheta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>A Rahim</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Eliana</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Chaudhary</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ngugi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mbanya</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Aye</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Latt</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Akanov</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Syed</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Tandon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Unnikrishnan</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Madhu</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Jawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chowdhury</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bajaj</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus - International Task Force.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2018</year>
            <season>Jan-Feb</season>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>132</fpage>
            <page-range>132-157</page-range>
            <pub-id pub-id-type="pmid">29535952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skillman</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>The pharmacology of sulfonylureas.</article-title>
            <source>Am J Med</source>
            <year>1981</year>
            <month>Feb</month>
            <volume>70</volume>
            <issue>2</issue>
            <fpage>361</fpage>
            <page-range>361-72</page-range>
            <pub-id pub-id-type="pmid">6781341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <chapter-title>Sulfonylureas, Second Generation</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>3</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">31643463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toyota</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>[Sulfonylurea drug--a new sulfonylurea drug for type 2 diabetes].</article-title>
            <source>Nihon Rinsho</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>57</volume>
            <issue>3</issue>
            <fpage>695</fpage>
            <page-range>695-701</page-range>
            <pub-id pub-id-type="pmid">10199156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Basit</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Riaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fawwad</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected].</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2012</year>
            <volume>8</volume>
            <fpage>463</fpage>
            <page-range>463-72</page-range>
            <pub-id pub-id-type="pmid">23028231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McIntosh</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dolovich</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Houlden</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis.</article-title>
            <source>Open Med</source>
            <year>2012</year>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>e62</fpage>
            <page-range>e62-74</page-range>
            <pub-id pub-id-type="pmid">23696771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Colagiuri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.</article-title>
            <source>Diabetes Res Clin Pract</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>110</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-81</page-range>
            <pub-id pub-id-type="pmid">26361859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sherifali</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nerenberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pullenayegum</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Gerstein</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis.</article-title>
            <source>Diabetes Care</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>8</issue>
            <fpage>1859</fpage>
            <page-range>1859-64</page-range>
            <pub-id pub-id-type="pmid">20484130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirst</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Farmer</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Dyar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lung</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis.</article-title>
            <source>Diabetologia</source>
            <year>2013</year>
            <month>May</month>
            <volume>56</volume>
            <issue>5</issue>
            <fpage>973</fpage>
            <page-range>973-84</page-range>
            <pub-id pub-id-type="pmid">23494446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <chapter-title>Sulfonylureas, First Generation</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>3</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">31644148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <chapter-title>Metiglinide Analogues</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>5</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">31643490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riddle</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Combining sulfonylureas and other oral agents.</article-title>
            <source>Am J Med</source>
            <year>2000</year>
            <month>Apr</month>
            <day>17</day>
            <volume>108 Suppl 6a</volume>
            <fpage>15S</fpage>
            <page-range>15S-22S</page-range>
            <pub-id pub-id-type="pmid">10764846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Proks</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reimann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gribble</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ashcroft</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Sulfonylurea stimulation of insulin secretion.</article-title>
            <source>Diabetes</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>51 Suppl 3</volume>
            <fpage>S368</fpage>
            <page-range>S368-76</page-range>
            <pub-id pub-id-type="pmid">12475777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inzucchi</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Oral antihyperglycemic therapy for type 2 diabetes: scientific review.</article-title>
            <source>JAMA</source>
            <year>2002</year>
            <month>Jan</month>
            <day>16</day>
            <volume>287</volume>
            <issue>3</issue>
            <fpage>360</fpage>
            <page-range>360-72</page-range>
            <pub-id pub-id-type="pmid">11790216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colagiuri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matthews</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Leiter</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Sesti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marre</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents.</article-title>
            <source>Diabetes Res Clin Pract</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>143</volume>
            <fpage>1</fpage>
            <page-range>1-14</page-range>
            <pub-id pub-id-type="pmid">29802958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hambrock</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>L&#x000f6;ffler-Walz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Quast</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides.</article-title>
            <source>Br J Pharmacol</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>136</volume>
            <issue>7</issue>
            <fpage>995</fpage>
            <page-range>995-1004</page-range>
            <pub-id pub-id-type="pmid">12145099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lv</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms and Characteristics of Sulfonylureas and Glinides.</article-title>
            <source>Curr Top Med Chem</source>
            <year>2020</year>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-56</page-range>
            <pub-id pub-id-type="pmid">31884929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <collab>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group</collab>
            <article-title>KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.</article-title>
            <source>Kidney Int</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>98</volume>
            <issue>4S</issue>
            <fpage>S1</fpage>
            <page-range>S1-S115</page-range>
            <pub-id pub-id-type="pmid">32998798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prendergast</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.</article-title>
            <source>Clin Pharm</source>
            <year>1984</year>
            <season>Sep-Oct</season>
            <volume>3</volume>
            <issue>5</issue>
            <fpage>473</fpage>
            <page-range>473-85</page-range>
            <pub-id pub-id-type="pmid">6435940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>J&#x000f6;nsson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rydberg</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sterner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Melander</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1998</year>
            <month>Feb</month>
            <volume>53</volume>
            <issue>6</issue>
            <fpage>429</fpage>
            <page-range>429-35</page-range>
            <pub-id pub-id-type="pmid">9551701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>W&#x000e5;hlin-Boll</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Melander</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sartor</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Scherst&#x000e9;n</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Influence of food intake on the absorption and effect of glipizide in diabetics and in healthy subjects.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1980</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>279</fpage>
            <page-range>279-83</page-range>
            <pub-id pub-id-type="pmid">7002565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association</collab>
            <article-title>9. Pharmacologic Approaches to Glycemic Treatment: <italic>Standards of Medical Care in Diabetes-2020</italic>.</article-title>
            <source>Diabetes Care</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>Suppl 1</issue>
            <fpage>S98</fpage>
            <page-range>S98-S110</page-range>
            <pub-id pub-id-type="pmid">31862752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenkranz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Profozic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Metelko</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Mrzljak</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Malerczyk</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment.</article-title>
            <source>Diabetologia</source>
            <year>1996</year>
            <month>Dec</month>
            <volume>39</volume>
            <issue>12</issue>
            <fpage>1617</fpage>
            <page-range>1617-24</page-range>
            <pub-id pub-id-type="pmid">8960852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishibashi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Takashina</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The effect of timing on gliclazide absorption and action.</article-title>
            <source>Hiroshima J Med Sci</source>
            <year>1990</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-9</page-range>
            <pub-id pub-id-type="pmid">2373640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naidoo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Virendra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Layla</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effects of gliclazide dose escalation on postprandial hyperglycemia in type 2 diabetes mellitus: A prospective, open-label, case-controlled, dose-escalation study.</article-title>
            <source>Curr Ther Res Clin Exp</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>67</volume>
            <issue>2</issue>
            <fpage>81</fpage>
            <page-range>81-102</page-range>
            <pub-id pub-id-type="pmid">24678087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khandelwal</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Modern Sulfonylureas Strike Back - Exploring the Freedom of Flexibility.</article-title>
            <source>Eur Endocrinol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>20</fpage>
            <page-range>20-22</page-range>
            <pub-id pub-id-type="pmid">30349590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drouin</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Diamicron MR once daily is effective and well tolerated in type 2 diabetes: a double-blind, randomized, multinational study.</article-title>
            <source>J Diabetes Complications</source>
            <year>2000</year>
            <season>Jul-Aug</season>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>185</fpage>
            <page-range>185-91</page-range>
            <pub-id pub-id-type="pmid">11004426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grajower</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Horne</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Clinical Management of Intermittent Fasting in Patients with Diabetes Mellitus.</article-title>
            <source>Nutrients</source>
            <year>2019</year>
            <month>Apr</month>
            <day>18</day>
            <volume>11</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">31003482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Landgraf</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aberle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Birkenfeld</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Gallwitz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kellerer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller-Wieland</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nauck</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Reuter</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Therapy of Type 2 Diabetes.</article-title>
            <source>Exp Clin Endocrinol Diabetes</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>127</volume>
            <issue>S 01</issue>
            <fpage>S73</fpage>
            <page-range>S73-S92</page-range>
            <pub-id pub-id-type="pmid">31860927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association</collab>
            <article-title>6. Glycemic Targets: <italic>Standards of Medical Care in Diabetes-2020</italic>.</article-title>
            <source>Diabetes Care</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>Suppl 1</issue>
            <fpage>S66</fpage>
            <page-range>S66-S76</page-range>
            <pub-id pub-id-type="pmid">31862749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klein-Schwartz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Stassinos</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Isbister</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Treatment of sulfonylurea and insulin overdose.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>496</fpage>
            <page-range>496-504</page-range>
            <pub-id pub-id-type="pmid">26551662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Canadian Diabetes Association Clinical Practice Guidelines Expert Committee</collab>
              <name>
                <surname>Clayton</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Yale</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Hypoglycemia.</article-title>
            <source>Can J Diabetes</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>37 Suppl 1</volume>
            <fpage>S69</fpage>
            <page-range>S69-71</page-range>
            <pub-id pub-id-type="pmid">24070966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Venkataraman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bantwal</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shaikh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saboo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Ramachandran</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Hypoglycemia: The neglected complication.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>819</fpage>
            <page-range>819-34</page-range>
            <pub-id pub-id-type="pmid">24083163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Webb</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Jarvis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Seidu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khunti</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The right place for Sulphonylureas today.</article-title>
            <source>Diabetes Res Clin Pract</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>157</volume>
            <fpage>107836</fpage>
            <pub-id pub-id-type="pmid">31479704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thul&#x000e9;</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Umpierrez</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Sulfonylureas: a new look at old therapy.</article-title>
            <source>Curr Diab Rep</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>473</fpage>
            <pub-id pub-id-type="pmid">24563333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwartz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Herman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies.</article-title>
            <source>Postgrad Med</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>127</volume>
            <issue>5</issue>
            <fpage>480</fpage>
            <page-range>480-93</page-range>
            <pub-id pub-id-type="pmid">25913393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association</collab>
            <article-title>8. Obesity Management for the Treatment of Type 2 Diabetes: <italic>Standards of Medical Care in Diabetes-2021</italic>.</article-title>
            <source>Diabetes Care</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>Suppl 1</issue>
            <fpage>S100</fpage>
            <page-range>S100-S110</page-range>
            <pub-id pub-id-type="pmid">33298419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2.</article-title>
            <source>Drugs</source>
            <year>1981</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>295</fpage>
            <page-range>295-320</page-range>
            <pub-id pub-id-type="pmid">7030708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riddle</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm.</article-title>
            <source>Diabetes Care</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>42</volume>
            <issue>12</issue>
            <fpage>2161</fpage>
            <page-range>2161-2163</page-range>
            <pub-id pub-id-type="pmid">31748210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yandrapalli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jolly</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Horblitt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sanaani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.</article-title>
            <source>Postgrad Med</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>129</volume>
            <issue>8</issue>
            <fpage>811</fpage>
            <page-range>811-821</page-range>
            <pub-id pub-id-type="pmid">28749197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Perkovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Marx</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pencina</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Toto</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Wanner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zinman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Baanstra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pfarr</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mattheus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Broedl</surname>
                <given-names>UC</given-names>
              </name>
              <name>
                <surname>Woerle</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>von Eynatten</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>DK</given-names>
              </name>
              <collab>CARMELINA&#x000ae; investigators</collab>
            </person-group>
            <article-title>Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA<sup>&#x000ae;</sup>): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.</article-title>
            <source>Cardiovasc Diabetol</source>
            <year>2018</year>
            <month>Mar</month>
            <day>14</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <pub-id pub-id-type="pmid">29540217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marx</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Zinman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kastelein</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Lachin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bluhmki</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johansen</surname>
                <given-names>OE</given-names>
              </name>
              <name>
                <surname>Woerle</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.</article-title>
            <source>Diab Vasc Dis Res</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>289</fpage>
            <page-range>289-301</page-range>
            <pub-id pub-id-type="pmid">23449634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seaquist</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Childs</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cryer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dagogo-Jack</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fish</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rosenzweig</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vigersky</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.</article-title>
            <source>Diabetes Care</source>
            <year>2013</year>
            <month>May</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>1384</fpage>
            <page-range>1384-95</page-range>
            <pub-id pub-id-type="pmid">23589542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association</collab>
            <article-title>12. Older Adults: <italic>Standards of Medical Care in Diabetes-2021</italic>.</article-title>
            <source>Diabetes Care</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>Suppl 1</issue>
            <fpage>S168</fpage>
            <page-range>S168-S179</page-range>
            <pub-id pub-id-type="pmid">33298423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <collab>American Geriatrics Society 2012 Beers Criteria Update Expert Panel</collab>
            <article-title>American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>616</fpage>
            <page-range>616-31</page-range>
            <pub-id pub-id-type="pmid">22376048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wulf</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Matuszewski</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Sulfonamide cross-reactivity: is there evidence to support broad cross-allergenicity?</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2013</year>
            <month>Sep</month>
            <day>01</day>
            <volume>70</volume>
            <issue>17</issue>
            <fpage>1483</fpage>
            <page-range>1483-94</page-range>
            <pub-id pub-id-type="pmid">23943179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Rife</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Limon</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Sulfonamide cross-reactivity: fact or fiction?</article-title>
            <source>Ann Pharmacother</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>290</fpage>
            <page-range>290-301</page-range>
            <pub-id pub-id-type="pmid">15644481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thornton</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Package inserts and the standard of care.</article-title>
            <source>Proc (Bayl Univ Med Cent)</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>502</fpage>
            <page-range>502-4</page-range>
            <pub-id pub-id-type="pmid">16278770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalra</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Singla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Use of oral anti-diabetic agents in pregnancy: a pragmatic approach.</article-title>
            <source>N Am J Med Sci</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-12</page-range>
            <pub-id pub-id-type="pmid">25709972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <collab>Guideline Development Group</collab>
            <article-title>Management of diabetes from preconception to the postnatal period: summary of NICE guidance.</article-title>
            <source>BMJ</source>
            <year>2008</year>
            <month>Mar</month>
            <day>29</day>
            <volume>336</volume>
            <issue>7646</issue>
            <fpage>714</fpage>
            <page-range>714-7</page-range>
            <pub-id pub-id-type="pmid">18369227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association</collab>
            <article-title>6. Glycemic Targets: <italic>Standards of Medical Care in Diabetes-2021</italic>.</article-title>
            <source>Diabetes Care</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>Suppl 1</issue>
            <fpage>S73</fpage>
            <page-range>S73-S84</page-range>
            <pub-id pub-id-type="pmid">33298417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chamberlain</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Doyle-Delgado</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Skolnik</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Diabetes Technology: Review of the 2019 American Diabetes Association Standards of Medical Care in Diabetes.</article-title>
            <source>Ann Intern Med</source>
            <year>2019</year>
            <month>Sep</month>
            <day>17</day>
            <volume>171</volume>
            <issue>6</issue>
            <fpage>415</fpage>
            <page-range>415-420</page-range>
            <pub-id pub-id-type="pmid">31404925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mannucci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Antenore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giorgino</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Scavini</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effects of Structured Versus Unstructured Self-Monitoring of Blood Glucose on Glucose Control in Patients With Non-insulin-treated Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.</article-title>
            <source>J Diabetes Sci Technol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>183</fpage>
            <page-range>183-189</page-range>
            <pub-id pub-id-type="pmid">28697625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ioannidis</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Diabetes treatment in patients with renal disease: Is the landscape clear enough?</article-title>
            <source>World J Diabetes</source>
            <year>2014</year>
            <month>Oct</month>
            <day>15</day>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>651</fpage>
            <page-range>651-8</page-range>
            <pub-id pub-id-type="pmid">25317242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tuttle</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Bilous</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Goldstein-Fuchs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Kalantar-Zadeh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Narva</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Navaneethan</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Neumiller</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>UD</given-names>
              </name>
              <name>
                <surname>Ratner</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Whaley-Connell</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Molitch</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Diabetic kidney disease: a report from an ADA Consensus Conference.</article-title>
            <source>Diabetes Care</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>10</issue>
            <fpage>2864</fpage>
            <page-range>2864-83</page-range>
            <pub-id pub-id-type="pmid">25249672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dougherty</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Klein-Schwartz</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Octreotide's role in the management of sulfonylurea-induced hypoglycemia.</article-title>
            <source>J Med Toxicol</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>199</fpage>
            <page-range>199-206</page-range>
            <pub-id pub-id-type="pmid">20352540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quadrani</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Spiller</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Widder</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Five year retrospective evaluation of sulfonylurea ingestion in children.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>1996</year>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>267</fpage>
            <page-range>267-70</page-range>
            <pub-id pub-id-type="pmid">8667462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association</collab>
            <article-title>6. Glycemic Targets: <italic>Standards of Medical Care in Diabetes-2019</italic>.</article-title>
            <source>Diabetes Care</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>42</volume>
            <issue>Suppl 1</issue>
            <fpage>S61</fpage>
            <page-range>S61-S70</page-range>
            <pub-id pub-id-type="pmid">30559232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Layman</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Clifton</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gannon</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Krauss</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Nuttall</surname>
                <given-names>FQ</given-names>
              </name>
            </person-group>
            <article-title>Protein in optimal health: heart disease and type 2 diabetes.</article-title>
            <source>Am J Clin Nutr</source>
            <year>2008</year>
            <month>May</month>
            <volume>87</volume>
            <issue>5</issue>
            <fpage>1571S</fpage>
            <page-range>1571S-1575S</page-range>
            <pub-id pub-id-type="pmid">18469290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Destree</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vercellino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Interventions to Improve Adherence to a Hypoglycemia Protocol.</article-title>
            <source>Diabetes Spectr</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>195</fpage>
            <page-range>195-201</page-range>
            <pub-id pub-id-type="pmid">28848314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cryer</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Shamoon</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Hypoglycemia in diabetes.</article-title>
            <source>Diabetes Care</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>1902</fpage>
            <page-range>1902-12</page-range>
            <pub-id pub-id-type="pmid">12766131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Villani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Courten</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zoungas</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Emergency treatment of hypoglycaemia: a guideline and evidence review.</article-title>
            <source>Diabet Med</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>9</issue>
            <fpage>1205</fpage>
            <page-range>1205-1211</page-range>
            <pub-id pub-id-type="pmid">28477413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sherman</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Lariccia</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Glucagon Therapy: A Comparison of Current and Novel Treatments.</article-title>
            <source>Diabetes Spectr</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>347</fpage>
            <page-range>347-351</page-range>
            <pub-id pub-id-type="pmid">33223773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r68">
          <label>68</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Labib</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yosipovitch</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <chapter-title>Skin Manifestations of Diabetes Mellitus</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Anawalt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blackman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corpas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Dhatariya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dungan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Korbonits</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kuohung</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Laferr&#x000e8;re</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>McLachlan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>New</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Purnell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Trence</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <source>Endotext [Internet]</source>
            <publisher-name>MDText.com, Inc.</publisher-name>
            <publisher-loc>South Dartmouth (MA)</publisher-loc>
            <year>2022</year>
            <month>4</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">29465926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tabish</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Is Diabetes Becoming the Biggest Epidemic of the Twenty-first Century?</article-title>
            <source>Int J Health Sci (Qassim)</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>V</fpage>
            <page-range>V-VIII</page-range>
            <pub-id pub-id-type="pmid">21475425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glovaci</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>ND</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of Diabetes Mellitus and Cardiovascular Disease.</article-title>
            <source>Curr Cardiol Rep</source>
            <year>2019</year>
            <month>Mar</month>
            <day>04</day>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>21</fpage>
            <pub-id pub-id-type="pmid">30828746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Impact of nurse champion on quality of care and outcomes in type 2 diabetes patients.</article-title>
            <source>Int J Evid Based Healthc</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-13</page-range>
            <pub-id pub-id-type="pmid">30520763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiel</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>McCord</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Pharmacist impact on clinical outcomes in a diabetes disease management program via collaborative practice.</article-title>
            <source>Ann Pharmacother</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>39</volume>
            <issue>11</issue>
            <fpage>1828</fpage>
            <page-range>1828-32</page-range>
            <pub-id pub-id-type="pmid">16219894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hwang</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Gums</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Gums</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>The benefits of physician-pharmacist collaboration.</article-title>
            <source>J Fam Pract</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>66</volume>
            <issue>12</issue>
            <fpage>E1</fpage>
            <page-range>E1-E8</page-range>
            <pub-id pub-id-type="pmid">29202145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Briggs Early</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stanley</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Position of the Academy of Nutrition and Dietetics: The Role of Medical Nutrition Therapy and Registered Dietitian Nutritionists in the Prevention and Treatment of Prediabetes and Type 2 Diabetes.</article-title>
            <source>J Acad Nutr Diet</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>118</volume>
            <issue>2</issue>
            <fpage>343</fpage>
            <page-range>343-353</page-range>
            <pub-id pub-id-type="pmid">29389511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association</collab>
            <article-title>1. Strategies for Improving Care.</article-title>
            <source>Diabetes Care</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>39 Suppl 1</volume>
            <fpage>S6</fpage>
            <page-range>S6-12</page-range>
            <pub-id pub-id-type="pmid">26696683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29673.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katon</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Von Korff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ciechanowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ludman</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rutter</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>McGregor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McCulloch</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Collaborative care for patients with depression and chronic illnesses.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Dec</month>
            <day>30</day>
            <volume>363</volume>
            <issue>27</issue>
            <fpage>2611</fpage>
            <page-range>2611-20</page-range>
            <pub-id pub-id-type="pmid">21190455</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
